Last $7.24 USD
Change Today +0.25 / 3.58%
Volume 380.6K
PGNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

Audit Committee* - progenics pharmaceuticals (PGNX)

Name (Connections)Board RelationshipsTitleKey Developments
Nicole Williams M.B.A. 36 RelationshipsIndependent Director, Chairman of Audit Committee and Member of Nominating & Corporate Governance Committee 
Michael Kishbauch 43 RelationshipsDirector, Member of Compensation Committee and Member of Audit Committee 
Karen Ferrante M.D. 18 RelationshipsDirector, Member of Science & Strategy Committee and Member of Audit Committee 

Compensation Committee* - progenics pharmaceuticals (PGNX)

Name (Connections)Board RelationshipsTitle
Peter Crowley 88 RelationshipsChairman of the Board, Chairman of Compensation Committee and Member of Science & Strategy Committee
Michael Kishbauch 43 RelationshipsDirector, Member of Compensation Committee and Member of Audit Committee
PGNX Compensation vs. Industry
535.6K
361.0K
Chief Executive Officer
278.5K
266.6K
Chief Financial Officer
Share price activity for PROGENICS PHARMACEUTICALS (PGNX)
52 Week Price Performance
PGNX
Industry Average

Nominating Committee* - progenics pharmaceuticals (PGNX)

Name (Connections)Board RelationshipsTitleKey Developments
Paul Maddon M.D., Ph.D. 42 RelationshipsFounder, Vice Chairman and Chairman of Nominating & Corporate Governance CommitteeProgenics Pharmaceuticals, Inc. Announces Dr. Hagop Youssoufian Step Down as Executive Vice President, Research and Development
09/25/14
Nicole Williams M.B.A. 36 RelationshipsIndependent Director, Chairman of Audit Committee and Member of Nominating & Corporate Governance CommitteeProgenics Pharmaceuticals, Inc. Elects Paul J. Maddon as Director
06/18/14

Corporate Governance Committee* - progenics pharmaceuticals (PGNX)

Name (Connections)Board RelationshipsTitle
Paul Maddon M.D., Ph.D. 42 RelationshipsChairman of the Board, Chairman of Compensation Committee and Member of Science & Strategy Committee
Nicole Williams M.B.A. 36 RelationshipsDirector, Member of Compensation Committee and Member of Audit Committee
PGNX and Competitor
Insiders vs. External
Board
16%
84%
Progenics Pharmaceuticals, Inc.
9%
91%
Array BioPharma, Inc.
15%
85%
CTI BioPharma Corp.
9%
91%
Inovio Pharmaceuticals, Inc.
22%
78%
Dynavax Technologies Corporation
6%
94%
ZIOPHARM Oncology, Inc.
Insiders
External Board Members

Executive Committee* - progenics pharmaceuticals (PGNX)

Name (Connections)Board RelationshipsTitle
Charles Baker J.D. 11 RelationshipsFormer Independent Director, Chairman of Nominating & Corporate Governance Committee, Member of Audit Committee and Member of Compensation Committee
Mark Dalton J.D. 8 RelationshipsFormer Independent Director, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee
Paul Jacobson 4 RelationshipsFormer Non-Executive Co-Chairman, Member of Audit Committee, Member of Compensation Committee and Member of Nominating & Corporate Governance Committee
Paul Maddon M.D., Ph.D. 42 RelationshipsFounder, Vice Chairman and Chairman of Nominating & Corporate Governance Committee
Management Effectiveness Relative to the Industry
Return on Equity
NM
Return on Assets
NM
Return on Total Capital
NM
TEV/Total Revenue(LTM)
NM

Advisory Committee* - progenics pharmaceuticals (PGNX)

Name (Board Relationships)/Title Board Affiliations
David Agus 64 Relationships
Member of Cancer Scientific Advisory Board
No other board affiliations
Dennis Burton 40 Relationships
Member of Virology Scientific Advisory Board
No other board affiliations
Lawrence Chasin 18 Relationships
Member of Virology Scientific Advisory Board
No other board affiliations
Leonard Chess 45 Relationships
Member of Virology Scientific Advisory Board
No other board affiliations
Samuel Danishefsky 65 Relationships
Member of Cancer Scientific Advisory Board
No other board affiliations
Stephen Goff 61 Relationships
Scientific Advisor and Chairman of the Virology Scientific Advisory Board
No other board affiliations
Wayne Hendrickson 18 Relationships
Member of Virology Scientific Advisory Board
No other board affiliations
Warren Heston 18 Relationships
Member of Cancer Scientific Advisory Board
No other board affiliations
Philip Livingston 34 Relationships
Member of Cancer Scientific Advisory Board
No other board affiliations
John Mendelsohn 166 Relationships
Member of Cancer Scientific Advisory Board
No other board affiliations
Sherie Morrison 38 Relationships
Member of Virology Scientific Advisory Board
No other board affiliations
David Scheinberg 60 Relationships
Director, Member of Cancer Scientific Advisory Board and Chairman of Science & Strategy Committee
No other board affiliations
Robin Weiss 18 Relationships
Member of Virology Scientific Advisory Board
No other board affiliations
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGNX:US $7.24 USD +0.25

PGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $4.75 USD +0.11
CTI BioPharma Corp $2.40 USD +0.04
Dynavax Technologies Corp $15.62 USD +0.27
Inovio Pharmaceuticals Inc $9.36 USD +0.25
ZIOPHARM Oncology Inc $4.90 USD +0.14
View Industry Companies
 

Industry Analysis

PGNX

Industry Average

Valuation PGNX Industry Range
Price/Earnings 59.5x
Price/Sales 10.5x
Price/Book 3.7x
Price/Cash Flow 58.4x
TEV/Sales 8.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGENICS PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.